Isis Initiates Phase 1 Clinical Trial of SGLT2 Anti...( potentially a cost effective oral admin...)

Date:2/5/2009

, potentially, a cost effective oral administration for the treatment of diabetes. In addition, in a Phase 1 study in healthy volunteers, we will be able to gain valuable information regarding the drug's activity, which we will use to design a Phase 2 program," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "We have 19 drugs in our pipeline and with the efficiency of our antisense technology, we expect to continue to mature and expand our portfolio as drugs advance in clinical development and are added to the pipeline."

About SGLT2 and ISIS-SGLT2Rx

SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive target for the treatment of diabetes. In preclinical studies up to six months in duration, Isis has demonstrated in several animal species that ISIS-SGLT2Rx and other antisense inhibitors of SGLT2 effectively reduce target mRNA levels, increase urinary glucose excretion and consequently lower blood glucose levels and HbA1c without causing any changes in renal or hepatic function or dangerously low levels of blood sugar known as hypoglycemia. Observations in preclinical studies are consistent with expectations based on human subjects who have mutations in the SGLT2 gene and have increased urine glucose levels but are otherwise asymptomatic. ISIS-SGLT2Rx effectively and specifically inhibits the production of SGLT2 in the kidney in animals, and does not have any effect on a related gene product, SGLT1. In addition to being Isis' first second-generation antisense drug for a kidney target, ISIS-SGLT2Rx is also unique due to its 12 nucleotide length rather than the more typical 18 - 21 nucleotide sequences that comprise Isis' other drugs, an attribute that reduces the cost of manufacturing.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its
'/>"/>

SOURCE Isis Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia